Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP417562.RAw9z87VyaKR6A3ZaTa3aaLNj8AUNdB2aaqgyQLCrYewA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP417562.RAw9z87VyaKR6A3ZaTa3aaLNj8AUNdB2aaqgyQLCrYewA130_assertion type Assertion NP417562.RAw9z87VyaKR6A3ZaTa3aaLNj8AUNdB2aaqgyQLCrYewA130_head.
- NP417562.RAw9z87VyaKR6A3ZaTa3aaLNj8AUNdB2aaqgyQLCrYewA130_assertion description "[If the correct targets are carefully selected for inhibition in tumors in which the targets are present (clear cell histologic features and loss of VHL expression), then results should resemble those others have observed with targeted therapy, such as the use of STI-571 (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors or anti-HER2/neu (Herceptin; Genentech, South San Francisco, CA) for treatment of breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP417562.RAw9z87VyaKR6A3ZaTa3aaLNj8AUNdB2aaqgyQLCrYewA130_provenance.
- NP417562.RAw9z87VyaKR6A3ZaTa3aaLNj8AUNdB2aaqgyQLCrYewA130_assertion evidence source_evidence_literature NP417562.RAw9z87VyaKR6A3ZaTa3aaLNj8AUNdB2aaqgyQLCrYewA130_provenance.
- NP417562.RAw9z87VyaKR6A3ZaTa3aaLNj8AUNdB2aaqgyQLCrYewA130_assertion SIO_000772 14569078 NP417562.RAw9z87VyaKR6A3ZaTa3aaLNj8AUNdB2aaqgyQLCrYewA130_provenance.
- NP417562.RAw9z87VyaKR6A3ZaTa3aaLNj8AUNdB2aaqgyQLCrYewA130_assertion wasDerivedFrom befree-2016 NP417562.RAw9z87VyaKR6A3ZaTa3aaLNj8AUNdB2aaqgyQLCrYewA130_provenance.
- NP417562.RAw9z87VyaKR6A3ZaTa3aaLNj8AUNdB2aaqgyQLCrYewA130_assertion wasGeneratedBy ECO_0000203 NP417562.RAw9z87VyaKR6A3ZaTa3aaLNj8AUNdB2aaqgyQLCrYewA130_provenance.